Azeliragon dihydrochloride
Azeliragon dihydrochloride (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD). Azeliragon dihydrochloride also can cross the blood-brain barrier (BBB).
For research use only. We do not sell to patients.
- CAS No.: 1284150-65-7
- Formula: C32H40Cl3N3O2
- Molecular Weight:605.04
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1284150-65-7
-
Molecular Weight 605.04
-
Formula C32H40Cl3N3O2
-
SMILES
CCN(CCCOC1=CC=C(C=C1)C2=CN(C(CCCC)=N2)C3=CC=C(C=C3)OC4=CC=C(C=C4)Cl)CC.Cl.Cl
-
Synonyms
TTP488 dihydrochloride; PF-04494700 dihydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Bongarzone S, et al. Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective. J Med Chem. 2017 Sep 14;60(17):7213-7232. [Content Brief]
[2]. Burstein AH, et al. Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis. Clin Pharmacol Drug Dev. 2019 May;8(4):426-435. [Content Brief]
[3]. Chen Y, et al. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008 Sep 15;181(6):4272-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)